title: Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery.
abstract: In patients with respiratory failure and impairment of the left ventricle, arteriovenous extracorporeal membrane oxygenation (ECMO) offers further therapeutic options. Systemic anticoagulation is mandatory and heparin is routinely administrated. However, repeated exposure to heparin may cause heparin-induced thrombocytopenia (HIT) and carries a risk of thrombotic mortality and morbidity. We present a patient who developed HIT during ECMO support and was treated successfully and safely by fondaparinux. Fondaparinux can be used for thromboembolic treatment or prophylaxis in a patient with HIT.
authors.affiliation: Cardiovascular Surgery Clinic, Ahi Evren Gogus Kalp Damar Cerrahisi Education and Research Hospital, Trabzon - Turkey.
authors.forename: Ali Ihsan
authors.initials: AI
authors.lastname: Parlar
authors.forename: Ufuk
authors.initials: U
authors.lastname: Sayar
authors.forename: Deniz
authors.initials: D
authors.lastname: Cevirme
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Yuruk
authors.forename: Ilker
authors.initials: I
authors.lastname: Mataraci
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D020878:Device Removal; D057915:Drug Substitution; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects; D005260:Female; D000077425:Fondaparinux; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008943:Mitral Valve / Q000601:surgery*; D011134:Polysaccharides / Q000627:therapeutic use*; D012086:Reoperation; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux